Invest in eNavvi

Public Letter: eNavvi's Investment Opportunity Through Crowdsourcing

Dear Potential Investors, 

We are excited to announce a unique investment opportunity in eNavvi, a groundbreaking digital prescription pad platform that is transforming healthcare access and affordability. To support our mission and fuel our next phase of growth, eNavvi is introducing a Crowdsourcing Round for investors who share our vision for a more transparent and accessible healthcare system. 

Why Invest in eNavvi?  

eNavvi revolutionizes the way healthcare providers prescribe medication. We are pioneers in leveraging AI-driven technologies and a proprietary electronic prescription network to address critical issues in the prescription process. We have partnered with some of the largest cash price pharmacies, such as Cost Plus Drugs, DiRX, and Blueberry Pharmacy, and in process of expanding to over 4,000 Nationwide pharmacies including Safeway and Vons via the Team Cuban Card to ensure complete pricing transparency and broader medication accessibility. Our product facilitates seamless prescription transmission between clinicians and pharmacies. This approach significantly improves medication accessibility for patients while empowering clinicians with the tools they need to prescribe effectively and efficiently. 

Return on Investment 

Following the closure of a SAFE agreement with a post-money valuation of $2M in November 2023, eNavvi is currently positioned at a $7.5M valuation for this round. We believe eNavvi's valuation has increased due to the major achievements we have made since our previous raise. Since November, we have: completed a UI revamp, integrated Cost Plus and successfully sent Rx’s, created strategic partnerships, joined Team Cuban Card and received access to 1,700 local pharmacies (including Safeway, Kroger, and Albertsons), and achieved revenue. Due to all this progress, and based on a projection of 3,500 users by June 2025, using a 15x discounted cash flows (DCF) multiple, we believe $7.5M is a fair valuation cap.

We are strategically aiming for a qualified seed round valuation of $15M+ in late 2024. As eNavvi progresses, we are optimistic about increasing our revenue streams and achieving a state of positive cash flow, which we believe will offer substantial returns to our investors. However, this is not guaranteed.

Understanding SAFE's

A SAFE, or Simple Agreement for Future Equity, is an investment contract where investors provide capital to a company, with the agreement that their investment will later convert into equity during a subsequent qualified fundraising round (e.g., the next VC funding round). Designed by Y Combinator, SAFEs are a favored mechanism for startups to efficiently raise early-stage capital.

Anticipated Shareholder Exits

Investing in eNavvi comes with the anticipation of robust returns through several potential exit strategies:

1. Private Secondary Market: Upon reaching a valuation of $30M, we aim to establish a private secondary market, either via a Regulation A/A+ listing or through platforms like Carta, providing investors with liquidity opportunities by allowing them to sell their stock (expected timeline 2-3 years).
2. Company Stock Buyback: Upon reaching a valuation of $40M and achieving positive cash flow, eNavvi intends to initiate an optional stock buyback program, offering shareholders the chance to sell their shares back to the company based on the $40M valuation (expected timeline of 3-5 years).
3. Acquisition: Should eNavvi's valuation surpass $100M, we will consider a strategic exit via acquisition. In such an event, all existing shares would be liquidated by the acquiring entity (expected timeline of 5+ years).

We are forecasting a potential return of up to 5x on investment over a 5-year period.

Future projections are not guaranteed.

Upcoming Milestones for eNavvi in 2024: 

1. Launch Crowdfunding Round April 2024 - Open to all physician and non-physician investors. Raising $124K to further develop and expand our product 
2. Launch Nationwide Local Pharmacy Integration May 2024 – Access to 4000+ retail pharmacies through Team Cuban Card partnership 
3. Product Refinement from May to June 2024 - Enhancements based on insights from physicians.
4. New Mobile App Beta Launch on June 2024 - Initial release for user feedback
5. eNavvi's Official Launch on July 2024 - Public introduction of eNavvi platform
6. Incorporation of UpToDate by August 2024 - Support prescribers with evidence based drug information at point of prescribing
7. Subscriber Growth Goal by September 2024 - Achieve 1000 prescribers to mark at least 20% month-over-month growth
8. DME expansion by October 2024 - Offer cash price options for continuous glucose monitors, wound care supplies, etc
9. Pharmacy Network Expansion by November 2024 - Expand cash price medication and retail pharmacies offering
10. eNavviGPT integration by December 2024 - GPT based clinical decision support tool
11. Seed Funding Round Q3-Q4 2024 - Aiming for a valuation of $15+ million to fuel further growth

Your Investment Will Make a Difference:  

Your investment in eNavvi plays a pivotal role in our evolution. It's not just about financial returns; your input directly influences our mission to enhance healthcare delivery. Through your investment, you're contributing to making healthcare prescriptions more transparent, accessible, and efficient for everyone involved. As we grow our platform and network, your support is crucial for our advancement.

We invite you to join us on this journey to revolutionize healthcare prescribing practices. For more information and to express your interest in investing, please reach out to us directly. Together, we can make a significant impact on the lives of millions of patients and healthcare providers across the country. 

Thank you for considering this opportunity. 

Best regards, 

eNavvi Leadership Team